SPS
CLYM

Susquehanna Portfolio Strategies’s Climb Bio CLYM Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$75.7K Buy
+11,056
New +$63.8K ﹤0.01% 942
2025
Q4 		– Sell
-18,272
Closed -$36.7K – 1155
2025
Q3 		$36.7K Buy
+18,272
New +$33.9K ﹤0.01% 1025

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Susquehanna Portfolio Strategies's CLYM Position: Q1 2026 in Review

Susquehanna Portfolio Strategies opened a new position in Climb Bio (CLYM) in Q1 2026: 11,056 shares worth $75.7K. The stake represents ﹤0.01% of the portfolio and ranks #942 among its holdings. This is a return to the name: Susquehanna Portfolio Strategies previously reported a position in CLYM as recently as Q3 2025.

Susquehanna Portfolio Strategies first reported a position in CLYM in Q3 2025 and has held it in 2 quarters since. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • Susquehanna Portfolio Strategies held 11,056 shares of Climb Bio worth $75.7K as of Q1 2026.
  • Climb Bio was a new Susquehanna Portfolio Strategies position in Q1 2026.
  • Climb Bio made up ﹤0.01% of Susquehanna Portfolio Strategies's portfolio in Q1 2026, its #942 holding.
  • Susquehanna Portfolio Strategies first reported a position in Climb Bio in Q3 2025 and has held it in 2 quarters since.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q1 2026, filed 15 May 2026.